Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.
The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.
In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.
Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.
Lippman’s other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.